Resource Summary

Clinical Question:
Are the benefits worth the risks of ASA in primary prevention (patients with no history of cardiovascular disease (CVD))?

Bottom-line:
The majority of primary prevention patients will not benefit from daily ASA therapy. It is possible that there is net benefit in higher-risk primary prevention patients. Although the best risk level to initiate ASA is uncertain^ it may be those with a ≥15-20 percent risk of CVD over 10 years.


*** Original Documents can be found and downloaded using the link provided below ***

https://www.acfp.ca/tools-for-practice/

Publication Date: 2013-7-22
Last Updated on PCR: 2017-03-31 15:13:52